勘误:FcRH5×CD3双特异性抗体cevostamab治疗复发或难治性多发性骨髓瘤的I期试验
Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Nature Medicine刊发关于FcRH5×CD3双特异性抗体cevostamab治疗复发或难治性多发性骨髓瘤I期试验的勘误声明。该勘误指出,原文扩展数据图3b中两个子图的左侧x轴标签被错误标记为“No 1q gain or amp”,应更正为“1q normal”。此更正已同步更新至该文章的HTML和PDF版本。
- Author Correction
- Open access
- Published: 20 October 2026
- Adam D. Cohen ORCID: orcid.org/0000-0003-0939-38431 na1,
- Joshua Richter2 na1,
- Suzanne Trudel ORCID: orcid.org/0000-0001-7952-63523 na1,
- Alexander Lesokhin ORCID: orcid.org/0000-0001-9321-702X4 na1,
- Jacob P. Laubach5,
- Sheeba K. Thomas ORCID: orcid.org/0000-0001-8596-70586,
- Simon J. Harrison ORCID: orcid.org/0000-0003-4555-65827,
- Luciano J. Costa ORCID: orcid.org/0000-0001-5362-24698,
- Andrew Spencer9,
- Rafael Fonseca ORCID: orcid.org/0000-0002-5938-376910,
- Peter A. Forsberg11,
- Jesus G. Berdeja ORCID: orcid.org/0000-0003-4362-037612,
- Rayan Kaedbey13,
- Nizar J. Bahlis ORCID: orcid.org/0000-0001-7353-703414,
- Paula Rodriguez-Otero15,
- Maria-Victoria Mateos ORCID: orcid.org/0000-0003-2390-121816,
- Tulika Tyagi17,
- Divya Samineni17,
- Wenyu Liu17,
- Rin Nakamura17,
- Voleak Choeurng17,
- Chihunt Wong17,
- James Cooper17 &
- …
- Amrita Krishnan18
Nature Medicine (2026) Cite this article
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04522-3, published online 22 July 2026.
In the version of the article initially published, in Extended Data Fig. 3b, the left x-axis label of both panels was “No 1q gain or amp” but should have been “1q normal”. This correction has been made to the HTML and PDF versions of the article.
Author information
Author notes
These authors contributed equally: Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin.
Authors and Affiliations
Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA, USA
Adam D. Cohen
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Joshua Richter
Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
Suzanne Trudel
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
Alexander Lesokhin
Dana-Farber Cancer Institute, Boston, MA, USA
Jacob P. Laubach
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Sheeba K. Thomas
Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Simon J. Harrison
O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
Luciano J. Costa
Alfred Health-Monash University, Melbourne, Victoria, Australia
Andrew Spencer
Mayo Clinic in Arizona, Phoenix, AZ, USA
Rafael Fonseca
University of Colorado School of Medicine, Aurora, CO, USA
Peter A. Forsberg
Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN, USA
Jesus G. Berdeja
Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Rayan Kaedbey
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
Nizar J. Bahlis
Clínica Universidad de Navarra, Pamplona, Spain
Paula Rodriguez-Otero
Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (CIC) and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain
Maria-Victoria Mateos
Genentech, Inc., South San Francisco, CA, USA
Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong & James Cooper
City of Hope Duarte, Duarte, CA, USA
Amrita Krishnan
Authors
- Adam D. Cohen
- Joshua Richter
- Suzanne Trudel
- Alexander Lesokhin
- Jacob P. Laubach
- Sheeba K. Thomas
- Simon J. Harrison
- Luciano J. Costa
- Andrew Spencer
- Rafael Fonseca
- Peter A. Forsberg
- Jesus G. Berdeja
- Rayan Kaedbey
- Nizar J. Bahlis
- Paula Rodriguez-Otero
- Maria-Victoria Mateos
- Tulika Tyagi
- Divya Samineni
- Wenyu Liu
- Rin Nakamura
- Voleak Choeurng
- Chihunt Wong
- James Cooper
- Amrita Krishnan
Corresponding author
Correspondence to Adam D. Cohen.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Cohen, A.D., Richter, J., Trudel, S. et al. Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04757-0
Published: 20 October 2026
Version of record: 20 October 2026
DOI: https://doi.org/10.1038/s41591-026-04757-0
来源:Nature 健康护理主题 · nature.com